Figure INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage [see all figures in this series...]

Part (iii) Estimates for the sub-sample of new injecting drug users (injecting less than 2 years), 2006 to 2007

Notes:

Black squares are samples with national coverage; blue triangles are samples with subnational (including local or regional) coverage. Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Portugal, Cyprus, Romania and Slovenia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Part of data from Portugal and Hungary include non-IDUs and therefore may underestimate prevalence among IDUs (estimated proportion of non-IDUs in the samples not known).

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

Czech Republic: data are from 2003; Turkey: data are from 2004; Poland: data are from 2004-05

Related links:

Figure INF-6 part (iii).

For primary sources, study details and data before 2006, see Table INF-13 and Table INF-0.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page

Sources:

Reitox national focal points